Biotech Scan
Scan
Biotech Scan
raw scan snapshot — prices as of scan date, not live 60 rows · screens, not recommendations
Biotech ETFs (XBI/IBB) are ripping to near-ATH with RSI 74-76 and 35%+ above VWAP — sector is broadly extended; LABU (3x) and MRNA are parabolic; the only clean entries are the mid-tier basing names (AMGN, CRSP, GILD, NVO) and selective speculative names off lows.
Source: biotech-scan.json. Latest bar 2026-06-26 (VRTX stale at 2026-06-25).
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟠 Sector broadly extended — ETFs at/near ATH (XBI RSI 76, IBB RSI 74, LABU RSI 77); MRNA +82% vs VWAP (parabolic); ABBV at ATH; ILMN/INCY/KYMR/PTGX led this week |
| Leaders | ABBV (RSI 76.6, ATH, +18% 30D, +22% vs VWAP); RARE (RSI 75.7, +31.6% 30D, +15% vs VWAP); XBI (RSI 76.2, near ATH, +35.6% vs VWAP); MRNA (RSI 71.4, +41.3% 30D, +82% vs VWAP) |
| Laggards | SRPT (RSI 49.2, -9.5% 7D, collapse DC, -14.4% vs SMA200); ISRG (RSI 41.6, -10.6% 3M, collapse DC, -17.3% vs SMA200); REGN (RSI 50.7, -14.1% 3M, strong-down DC) |
| Froth flags | LABU +130.5% vs VWAP (truly parabolic); MRNA +82% vs VWAP; KYMR +51.1% vs VWAP; PTGX +49.2% vs VWAP; AMAT/AMD context: biotech is now as extended as semis on a VWAP-basis |
| Key insight | Biotech sector re-rate is real and broad (XBI +30% 3M, IBB +17% 3M) but all the ETF upside is priced near-term; the cleanest EOW entries are the non-frothy mid-caps: AMGN/GILD/NVO basing + spec names NTLA/COGT off big-volume runs |
Price Table
| Stock | Price | RSI | vs SMA20 | 7D% | 30D% | 3M% | 52wkHi% | Trend | Signal |
|---|---|---|---|---|---|---|---|---|---|
| ISRG | $404.70 | 41.6 ↓ | -1.6% | -0.3% | -3.3% | -10.6% | -33.0% | strong-down DC | ❌ Broken |
| SRPT | $16.85 | 49.2 | +2.8% | -9.5% | +1.0% | -15.6% | -33.5% | strong-down DC | ❌ Broken |
| REGN | $632.90 | 50.7 | +2.8% | +3.3% | +0.8% | -14.1% | -22.9% | strong-down DC | ❌ Avoid |
| ALNY | $291.37 | 49.4 | +0.1% | +4.9% | -1.4% | -8.2% | -41.2% | strong-down DC | ❌ Broken |
| NKTR | $63.65 | 48.4 | +4.5% | -4.0% | -2.7% | -7.3% | -41.6% | weak-down GC | ⚠️ Avoid |
| DXCM | $70.14 | 48.9 | -3.8% | -1.8% | -0.2% | +12.7% | -22.1% | up DC | 🔍 Watch |
| EDIT | $2.85 | 53.4 | +4.0% | -1.1% | -20.2% | +27.8% | -37.2% | weak-down GC | ⚠️ Caution |
| LEGN | $28.69 | 45.3 | -10.2% | 0.0% | +0.7% | +70.8% | -36.7% | strong-up GC | 🔍 Watch (pullback after run) |
| BNTX | $91.22 | 51.6 | +1.5% | -0.6% | -1.9% | +6.5% | -26.4% | strong-down DC | ⚠️ Avoid |
| GILD | $127.88 | 51.7 | +1.3% | -0.1% | -3.7% | -4.1% | -18.7% | down GC | 🔍 Watch (basing) |
| RXRX | $3.52 | 58.3 | +5.5% | +6.7% | +11.0% | +19.7% | -51.0% | weak-up DC | 🔍 Watch |
| CRSP | $54.92 | 57.4 | +3.8% | -0.8% | +2.6% | +20.0% | -30.0% | weak-up DC | 🔍 Watch |
| MDT | $80.98 | 55.2 | +2.0% | +2.5% | +6.6% | -7.1% | -23.8% | weak-up DC | 🔍 Watch |
| AMGN | $358.33 | 62.3 | +3.9% | +3.2% | +6.6% | +3.5% | -8.4% | strong-up GC | 📈 Accumulate |
| BEAM | $34.81 | 61.1 | +10.0% | -4.8% | +9.2% | +56.9% | -5.6% | strong-up GC | 🔍 Watch (extended) |
| DNA | $10.25 | 66.7 | +16.7% | +8.7% | +17.7% | +72.9% | -41.7% | up DC | 🔍 Watch |
| IQV | $191.14 | 63.7 | +5.7% | +13.6% | +15.4% | +16.7% | -22.6% | weak-up DC | 🔍 Watch |
| BMRN | $59.00 | 64.6 | +5.1% | +3.7% | +12.6% | +9.0% | -11.0% | up DC | 🔒 Hold |
| A | $136.01 | 63.9 | +2.9% | +7.4% | +17.4% | +23.7% | -15.1% | up DC | 🔒 Hold |
| TMO | $513.03 | 66.5 | +6.9% | +10.1% | +12.6% | +8.5% | -20.3% | weak-up DC | 🔒 Hold |
| NVO | $48.07 | 68.2 | +8.5% | +5.2% | +7.9% | +38.3% | -33.1% | up DC | 📈 Accumulate |
| COGT | $38.10 | 70.1 | +12.2% | +7.5% | +10.4% | +5.5% | -12.9% | strong-up GC | 🔒 Hold |
| NTLA | $16.68 | 65.7 | +17.1% | +2.3% | +24.1% | +34.8% | -41.0% | strong-up GC | 🔍 Watch |
| DHR | $196.19 | 69.3 | +7.3% | +10.1% | +13.3% | +8.1% | -19.2% | weak-up DC | 🔒 Hold |
| BIIB | $216.03 | 69.3 | +9.3% | +2.8% | +9.7% | +17.5% | -0.9% | strong-up GC | 🔒 Hold |
| VRTX‡ | $480.18 | 69.2 | +6.8% | +4.8% | +10.2% | +5.8% | -5.5% | up DC | 🔒 Hold |
| INCY | $113.75 | 68.9 | +11.1% | +5.9% | +16.9% | +26.0% | -1.6% | strong-up GC | 🔒 Hold |
| IONS | $81.18 | 70.8 | +8.2% | +5.2% | +6.1% | +12.5% | -6.4% | up DC | 🔒 Hold |
| ILMN | $176.55 | 67.5 | +6.8% | +11.0% | +17.6% | +50.0% | -3.4% | strong-up GC | 🔒 Hold (+43% vs VWAP) |
| LLY | $1,208.12 | 72.7 ↑ | +7.7% | +2.7% | +11.6% | +37.8% | -0.6% | strong-up GC | ⚠️ Extended (ATH, +33.6% vs VWAP) |
| MRNA | $67.27 | 71.4 ↑ | +25.9% | +1.8% | +41.3% | +35.7% | -2.9% | strong-up GC | ⚠️ PARABOLIC (+82% vs VWAP) |
| PTGX | $121.88 | 71.2 ↑ | +12.8% | +6.1% | +19.2% | +23.2% | -3.5% | strong-up GC | ⚠️ Extended (+49.2% vs VWAP) |
| KYMR | $108.12 | 70.2 | +25.2% | +16.3% | +32.3% | +38.3% | -16.9% | strong-up GC | ⚠️ Extended (+51.1% vs VWAP — parabolic flag) |
| RARE | $30.77 | 75.7 ↑ | +22.3% | +4.3% | +31.6% | +58.8% | -27.4% | up DC | ⚠️ Extended (+15.4% vs VWAP) |
| ABBV | $253.35 | 76.6 ↑ | +12.1% | +7.3% | +17.6% | +22.0% | 0.0% | up DC | ⚠️ Extended (ATH, +18.1% vs VWAP) |
| IBB | $187.36 | 74.1 ↑ | +8.5% | +4.7% | +10.3% | +16.8% | -0.7% | strong-up GC | ⚠️ Extended (+17.3% vs VWAP, near ATH) |
| IBBQ | $32.23 | 73.8 ↑ | +8.2% | +3.5% | +9.3% | +16.9% | -0.4% | strong-up GC | ⚠️ Extended (+15.1% vs VWAP, near ATH) |
| XBI | $155.38 | 76.2 ↑ | +13.2% | +5.0% | +15.7% | +30.1% | -0.3% | strong-up GC | ⚠️ Extended (+35.6% vs VWAP, near ATH) |
| LABU | $276.16 | 77.1 ↑ | +41.3% | +15.1% | +48.5% | +99.4% | -1.1% | strong-up GC | 🔴 PARABOLIC (+130.5% vs VWAP) |
‡VRTX stale (2026-06-25 bar).
Tier Analysis
Collapsing / Broken (RSI < 52, DC, below SMA200)
- ISRG ($404.70, RSI 42) — Collapse, DC, -17.3% vs SMA200, -33% from ATH. Surgical robotics overhang (J&J Ottava / Medtronic Hugo). No entry.
- SRPT ($16.85, RSI 49) — Sarepta: strong-down, DC, -14.4% vs SMA200, -9.5% 7D on 4x normal volume. Duchenne setback price action. Avoid.
- REGN ($632.90, RSI 51) — Regeneron: strong-down, DC, -14.1% 3M, -9.2% vs SMA200. Dupixent/eylea concerns. Avoid.
- ALNY ($291.37, RSI 49) — Alnylam: strong-down, DC, -21.3% vs SMA200, -41.2% from ATH. SiRNA platform de-rated. Avoid.
- BNTX ($91.22, RSI 52) — BioNTech: strong-down, DC, -8.1% vs SMA200. mRNA franchise hollowing out post-COVID. Avoid.
- NKTR ($63.65, RSI 48) — Nektar: weak-down, -41.6% from ATH. Pulled back -4% 7D off a prior big 3Y run. Wait.
Neutral / Basing (RSI 53–65)
- GILD ($127.88, RSI 52) — Gilead: basing, GC intact, -0.2% vs SMA200. Flat week but technically on the SMA200 — cleanest mid-cap watch in the scan.
- CRSP ($54.92, RSI 57) — CRISPR: weak-up, DC, -1.1% vs SMA200, +20% 3M. Below the 200 but basing. Gene-editing re-rate ongoing.
- AMGN ($358.33, RSI 62) — Amgen: strong-up, GC, +8.7% vs SMA200, +6.6% 30D. Cleanest large-cap accumulate in the scan — not extended.
- NVO ($48.07, RSI 68) — Novo Nordisk (ADR): GLP-1 recovery, +38.3% 3M, +2.9% vs SMA200, +1.3% vs VWAP — not frothy despite the run. DC still in place. Accumulate on any SMA20 retest.
- TMO ($513.03, RSI 67) — Thermo Fisher: weak-up, DC, -2.3% vs SMA200, +12.6% 30D. Lab-tools bouncing; still below SMA200 — wait for reclaim.
- DHR ($196.19, RSI 69) — Danaher: weak-up, DC, -3.6% vs SMA200, +13.3% 30D bounce. Same pattern as TMO — relief rally not yet a reclaim.
Momentum / Leading (RSI 65–74)
- ILMN ($176.55, RSI 68) — Illumina: strong-up, GC, +37.4% vs SMA200, +11% 7D, +50% 3M. Big breakout. Extended at +43% vs VWAP but thesis is turning; hold.
- BIIB ($216.03, RSI 69) — Biogen: strong-up, GC, +22.6% vs SMA200, near ATH. Alzheimer drug re-rate holding. Hold.
- INCY ($113.75, RSI 69) — Incyte: strong-up, GC, +16.9% vs SMA200, near ATH (-1.6%). JAK inhibitor franchise. Hold.
- NTLA ($16.68, RSI 66) — Intellia: strong-up, GC, +22.9% vs SMA200, +24.1% 30D. In-vivo gene-editing momentum.
Extended / Parabolic (RSI > 71)
- ABBV ($253.35, RSI 77) — AbbVie: at ATH, +17.6% 30D, +18.1% vs VWAP. Don't chase.
- MRNA ($67.27, RSI 71) — Moderna: +82% vs VWAP (poc at $25.22 — price nearly 3x above the long-term VWAP). +41.3% 30D. The most extended large-cap name.
- KYMR ($108.12, RSI 70) — Kymera: +51.1% vs VWAP (parabolic); +32.3% 30D, 3.6x avg volume this week. Clinical-stage; frothy.
- PTGX ($121.88, RSI 71) — Protagonist: +49.2% vs VWAP, near ATH, +19.2% 30D.
- XBI ($155.38, RSI 76) — ETF: +35.6% vs VWAP, near ATH. Don't add to sector ETF here.
- LABU ($276.16, RSI 77) — 3x Biotech: +130.5% vs VWAP — parabolic leveraged ETF. If owned, protect gains; do not initiate.
Entry Zones
| Stock | Price | Zone | RSI | 30D% | Setup |
|---|---|---|---|---|---|
| AMGN | $358.33 | <$350 (SMA20 retest) | 62.3 | +6.6% | Large-cap basing; GC; +8.7% vs SMA200; not extended (+10.9% vs VWAP) |
| NVO | $48.07 | <$46 (SMA20 retest) | 68.2 | +7.9% | GLP-1 recovery; +38.3% 3M; +2.9% vs SMA200; +1.3% vs VWAP = not frothy |
| GILD | $127.88 | <$126 (SMA20 support) | 51.7 | -3.7% | Basing on SMA200; GC; +2.5% vs VWAP; oversold-adjacent, cleanest base setup |
| NTLA | $16.68 | <$16 | 65.7 | +24.1% | In-vivo gene editing; GC; +22.9% vs SMA200; +23.2% vs VWAP — not parabolic |
| ILMN | $176.55 | <$165 (SMA20) | 67.5 | +17.6% | Breakout confirmed; GC; +37.4% vs SMA200; only add on pullback to SMA20 |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| 🔒 HOLD | BIIB, INCY, AMGN, IONS, ILMN, COGT, BMRN, A, IQV, TMO, DHR | Uptrends / breakouts intact; thesis active; don't sell strength |
| 📈 ACCUMULATE | AMGN, NVO, GILD | Not extended; basing on or near SMA200; best risk/reward in sector |
| 🔍 WATCH | NTLA, CRSP, LEGN, RXRX, DXCM, DNA | Biotech speculation — wait for volume + confirmation; don't front-run |
| ⚠️ EXTENDED / DON'T CHASE | ABBV, LLY, MRNA, KYMR, PTGX, XBI, IBB, IBBQ, RARE | RSI 70-77; 15-82% above VWAP; near-ATH; fully priced short-term |
| 🔴 PARABOLIC — PROTECT | LABU | +130.5% vs VWAP, RSI 77; leveraged ETF at risk of violent reversal; trail stop if owned |
| ❌ BROKEN / AVOID | ISRG, SRPT, REGN, ALNY, BNTX | Collapse/strong-down regimes; DC; below SMA200; structural de-rates |
What Changed This Week (EOW)
- Biotech ETFs went parabolic — XBI +5% 7D (RSI 76, near ATH, +35.6% vs VWAP), IBB +4.7% 7D (RSI 74, near ATH). The sector re-rate that started with MRNA/LLY has now broadened into the ETFs themselves; buying the ETF here is chasing.
- ABBV broke to ATH — RSI 77, +7.3% 7D, +17.6% 30D, +18.1% vs VWAP. AbbVie is the week's standout large-cap print; confirms the biotech/pharma rotation bid.
- KYMR +16.3% 7D — The week's top gainer in scan; +51.1% vs VWAP is a froth flag; clinical catalyst-driven.
- ILMN +11% 7D — Illumina confirmed breakout; +37.4% vs SMA200 and +50% 3M; now in "hold" territory (extended to add, but don't sell).
- ISRG still collapsing — RSI 42, -10.6% 3M, -33% from ATH; DC confirmed; focused medtech remains the sector's structural loser.
- MRNA froth deepens — +41.3% 30D, +82% vs VWAP; poc at $25.22; the stock has tripled off its base but is trading far above any reasonable VWAP anchor. Hold if owned, don't initiate.
Key Discoveries
| Discovery | Implication |
|---|---|
| XBI/IBB both >35% vs VWAP at near-ATH | Sector ETF level is not an entry — the broad re-rate is fully priced in the ETFs; alpha is now stock-specific |
| MRNA +82% vs VWAP with poc at $25 | The "price of control" is $25 — this run is momentum-driven, not mean-reverting; any selloff could be deep |
| AMGN/NVO are the only large-caps not extended vs VWAP | Two quality accumulate setups in a fully extended sector |
Mistakes (Don't Repeat)
| Mistake | Lesson |
|---|---|
| Chasing XBI/IBB on sector breakout | At +35% vs VWAP and RSI 76, the ETF buy is a late-cycle momentum trade, not a thesis entry |
| Treating ISRG's "intact" thesis tag as a buy signal | collapse + DC + below SMA200 = broken trend; thesis tag ≠ entry |
Open Questions
- ILMN at +43% vs VWAP: does the +50% 3M run have a second leg, or does it mean-revert to the SMA20 ($165) first?
- MRNA +82% vs VWAP: what's the catalyst that could hold this level? Without a clinical update, gravity is brutal.
- KYMR/PTGX: are these clinical catalyst names or just sector-beta levered to the XBI run?
Related
10 eventsNo direct external sources are attached to this read.